Reading BIO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIO free→Reading BIO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIO free→NYSEHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, and risk is moderate. The sector backdrop is a headwind, but compared with sector peers, BIO is typical. Peer multiples imply a price about 7% below where it trades (it looks expensive on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $289.28. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $289 BIO trades at 31× p/e, in line with its 29× p/e peer median. Our $271 fair value reflects that, low confidence. Analysts: $290–$320. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 7% near-term growth, in line with our forecast of about 0%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 3.02x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.45 → $1.75 (-28.7% / 30d). 0 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 20% of analysts rate Buy.
1 PT revisions / 30d. Avg target 7.7% above current price.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$117.
How much price usually moves either way.
On a bad day, this stock has moved -$322.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,886.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Ongoing losses may worry people about Bio-Rad's money and how it runs.
Confirms:Q2 earnings report shows losses greater than the previous quarter.
Disproves:Q2 earnings report shows profits or smaller losses than last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for BIO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On April 30, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$290.00 – $320.00 (median $315.00) · 4 analysts · as of 2026-05-25
Roughly priced in line with peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Life Sciences Tools & Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BIO Bio-Rad Laboratories | Typical Show detailsSector percentile: 37 of 100 | full | moderate |
TMO Thermo Fisher Scientific | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
DHR Danaher Corporation | Above typical Show detailsSector percentile: 97 of 100 | fair | moderate |
A Agilent Technologies | Above typical Show detailsSector percentile: 92 of 100 | full | moderate |
WAT Waters Corporation | Above typical Show detailsSector percentile: 90 of 100 | fair | moderate |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on achieving a non-GAAP operating margin between 10.0% and 12.0% for the fiscal year 2026.
Target revenue growth between a decline of 3.0% and an increase of 0.5% for the fiscal year 2026.
Why it matters: Operating margin shows if the company can make more money during tough times.
Confirms:Operating margin was over 12.0% for Q2 2026.
Disproves:Operating margin was below 10.0% for Q2 2026.
Why it matters: This range is a key target for the company. It shows if growth is improving or worsening.
Confirms:Q2 revenue growth lands within the -3.0% to 0.5% range.
Disproves:Q2 revenue growth falls below -3.0%.
Why it matters: Funding impacts Bio-Rad's Life Science segment, which is crucial for growth.
Confirms:Reports show academic research funding is rising a lot.
Disproves:Reports show academic research funding is dropping more.
Why it matters: A drop in revenue growth would signal a potential slowdown in the sector. This could impact Bio-Rad's performance and outlook.
Confirms:Revenue growth falls below the median level for the sector.
Disproves:Revenue growth remains above the median level for the sector.
Why it matters: The guidance will show if the company can recover from a weak Q1 and meet its goals.
Confirms:Management expects non-GAAP revenue to grow more than 0.5% in Q2.
Disproves:Management cuts Q2 guidance for non-GAAP revenue growth to less than -3.0%.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 21, 2026, at the annual meeting of stockholders (the “Annual Meeting”) of Bio-Rad Laboratories, Inc. (the “Company”), as further described in
Results of Operations and Financial Condition On February 12, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.